WILMINGTON, Del., Oct. 12, 2021 (GLOBE NEWSWIRE) —


Rigrodsky Law, P.A.


announces that it is investigating Adamas Pharmaceuticals, Inc. (“Adamas”) (NASDAQ GM:

ADMS

) regarding possible breaches of fiduciary duties and other violations of law related to Adamas’ agreement to be acquired by Supernus Pharmaceuticals, Inc. (NASDAQ GM:

SUPN

). Under the terms of the agreement, Adamas’ shareholders will receive $8.10 in cash and two non-tradeable contingent value rights collectively worth up to $1.00 per share.

To learn more about this investigation and your rights, visit:

https://www.rl-legal.com/cases-adamas-pharmaceuticals-inc

.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or


[email protected]


.

Rigrodsky Law, P.A.


, with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in


securities fraud and corporate class actions


nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky Law, P.A.

Seth D. Rigrodsky

Gina M. Serra

(888) 969-4242 (Toll Free)

(302) 295-5310

Fax: (302) 654-7530



[email protected]





https://rl-legal.com